Bristol Myers Squibb announced on Monday that it will invest approximately $2.3 billion to construct a new manufacturing facility in Houston, Texas. The New Jersey-based pharmaceutical company stated that the project is part of a broader $40 billion commitment to domestic investment in the United States.
The development follows a series of announcements from global drugmakers, including Eli Lilly, Johnson & Johnson, Roche, and Pfizer, regarding expanded U.S. manufacturing capacity. These investments occur as industry representatives have engaged in discussions with the Trump administration regarding manufacturing and potential tariffs.
According to Bristol Myers Squibb, the new site will consist of a 600,000-square-foot campus designed to produce small-molecule medicines, biologics, and antibody-drug conjugates. The company indicated the facility could be reconfigured or expanded in the future to accommodate changing drug development needs.
Texas Governor Greg Abbott announced that the state has offered the company a $4.89 million grant through the Texas Enterprise Fund. The governor also noted that the project qualifies for benefits under the state's Jobs, Energy, Technology and Innovation program.
The scale of the $2.3 billion project contributes to a wider industry shift toward domestic production. As major pharmaceutical firms move toward manufacturing more complex biologics and antibody-drug conjugates within the United States, the availability and supply chains for these specific classes of medicine may be increasingly localized. This shift follows the industry's response to federal pressure to increase U.S.-based manufacturing, which companies have used as a strategy to navigate potential tariff policies.
What happens next: Construction is scheduled to begin within a timeframe that allows for the project to generate jobs starting in 2027. The company expects the campus to be brought online by 2030. During this period, Bristol Myers Squibb will be eligible for state-level financial incentives, while the federal government continues to monitor domestic manufacturing benchmarks for the pharmaceutical industry. The company has not yet provided specific dates for the groundbreaking ceremony or the start of drug production.